サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179526

神経バイオマーカー市場：タイプ別（ゲノム、プロテオーム、メタボローム、その他）、用途別（アルツハイマー病、多発性硬化症、パーキンソン病） - 世界の機会分析および産業予測、2021-2031年

Neurological Biomarkers Market By Type (Genomic, Proteomic, Metabolomic, Others), By Application (Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 141 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
神経バイオマーカー市場：タイプ別（ゲノム、プロテオーム、メタボローム、その他）、用途別（アルツハイマー病、多発性硬化症、パーキンソン病） - 世界の機会分析および産業予測、2021-2031年
出版日: 2022年09月01日
発行: Allied Market Research
ページ情報: 英文 141 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

神経バイオマーカーは、神経変性疾患を患っている患者の生物学的状態や状況を示す測定可能な指標です。

脳疾患では、様々な脳細胞の代謝障害を反映する多くのマーカーが必要とされます。最近導入されたメタボローム解析法は、脳の代謝に関連する多数の生化学成分のプロファイリングに基づく神経疾患の研究に役立っています。

神経バイオマーカー市場の成長を促す主な要因としては、神経学的疾患にかかりやすい老年人口の増加、頭部外傷の増加、アルツハイマー病、パーキンソン病、多発性硬化症の有病率の上昇などが挙げられます。例えば、2020年に発表されたWHOの最新データによると、オーストラリアにおけるパーキンソン病の死亡者数は2,036人、総死亡者数の1.49%に達しています。年齢調整死亡率は人口10万人あたり3.35人で、オーストラリアは世界第131位にランクされています。WHOの2022年最新版によると、世界的にパーキンソン病による障害と死亡は、他のどの神経疾患よりも急速に増加しています。

例えば、全米多発性硬化症協会2019によると、米国では18歳以上の75万人から100万人がMSと共に生活しています。北東部や中西部では、南部よりもMSを患っている人が多くなっています。MSの罹患率は1955年以降、世界的に増加しています。米国におけるMSの最初の報告は1976年に発表され、123,00の症例が見つかりました。1990年の研究では、MSの300,000例が見つかりました。これは、2019年の推定患者数75万～100万人と比べても遜色ありません。

さらに、神経学は、アルツハイマー病、パーキンソン病、多発性硬化症の治療法として、個別化医療が重要視されつつある分野の一つです。神経バイオマーカーは、個別化医療において様々な範囲をカバーしており、最終的には神経バイオマーカーを組み込んだ診断の需要に拍車をかけています。したがって、個別化医療に対する需要の高まりが、神経バイオマーカー市場の成長を後押ししています。

さらに、低侵襲手術の需要の増加が、神経バイオマーカー製品の採用を促進しています。さらに、技術的進歩、さまざまな製品の発売、買収、提携、契約などの主要企業間の戦略が神経バイオマーカー市場の成長を促進します。例えば、2021年6月、ロシュグループの一員であるジェネンテックとその親会社であるロシュ・ホールディングAGは、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症（ALS）、自閉症などの衰弱性脳疾患および中枢神経系（CNS）の障害に対する新しい治療薬の開発を加速させるために、カリフォルニア大学サンフランシスコ校（UCSF）およびカリフォルニア大学バークレー校と提携すると発表しています。UCSFとUC Berkeleyは、10年間の共同研究期間中、Genentech社から最大5300万米ドルを受け取っていました。

しかし、アルツハイマー病、パーキンソン病、多発性硬化症の早期診断に関する倫理的問題が浮上していることが、市場の成長を阻害すると予想されます。厳しい政府の規制や神経バイオマーカー製品の高コストも、市場の成長を抑制しています。

さらに、患者数の増加、アルツハイマー病やパーキンソン病の非侵襲的診断技術の需要増加、創薬・開発における研究開発投資の増加、神経バイオマーカーに関する認知度の上昇により、費用対効果の高いバイオマーカー検査の開発に注目が集まっていることから、ヘルスケア事業の成長が予測されます。このため、予測期間中に主要企業が同市場に投資することで、有益な機会を提供できると予想されます。

神経バイオマーカー市場は、タイプ、用途、地域に基づいて区分されます。タイプ別では、ゲノミック、プロテオミック、メタボロミック、その他に分類されます。アプリケーション別では、アルツハイマー病、パーキンソン病、多発性硬化症に分類されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 神経バイオマーカー市場：タイプ別

  • 概要
    • 市場規模および予測
  • ゲノミック
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • プロテオミクス
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • メタボローム
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 神経バイオマーカー市場：用途別

  • 概要
    • 市場規模および予測
  • アルツハイマー型認知症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 多発性硬化症
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • パーキンソン病
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 神経バイオマーカー市場：地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米の市場規模・予測：タイプ別
    • 北米市場規模・予測：アプリケーション別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
  • 欧州
    • 主な動向と機会
    • 欧州市場規模・予測：タイプ別
    • 欧州市場規模・予測：アプリケーション別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：タイプ別
    • アジア太平洋地域の市場規模・予測：アプリケーション別
    • アジア太平洋地域の市場規模・予測：国別
      • 日本
      • 中国
      • インド
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：タイプ別
    • LAMEAの市場規模・予測：アプリケーション別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • サウジアラビア
      • LAMEAの残りの地域

第7章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主な発展

第8章 企業プロファイル

  • F. HOFFMANN-LA ROCHE LTD.
  • Bio-Rad Laboratories, Inc.
  • merck kgaa, darmstadt, germany
  • PERKINELMER INC.
  • shimadzu corporation
  • Thermo Fisher Scientific, Inc.
  • Quanterix
  • Neurobio
  • bioMerieux
  • MYRIAD RBM（MYRIAD GENETICS, INC.）
図表

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. NEUROLOGICAL BIOMARKERS MARKET, FOR GENOMIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. NEUROLOGICAL BIOMARKERS MARKET FOR GENOMIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. NEUROLOGICAL BIOMARKERS MARKET, FOR PROTEOMIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. NEUROLOGICAL BIOMARKERS MARKET FOR PROTEOMIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. NEUROLOGICAL BIOMARKERS MARKET, FOR METABOLOMIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. NEUROLOGICAL BIOMARKERS MARKET FOR METABOLOMIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. NEUROLOGICAL BIOMARKERS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. NEUROLOGICAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 11. NEUROLOGICAL BIOMARKERS MARKET, FOR ALZHEIMER'S DISEASE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. NEUROLOGICAL BIOMARKERS MARKET, FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. NEUROLOGICAL BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. NEUROLOGICAL BIOMARKERS MARKET, FOR PARKINSON'S DISEASE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. NEUROLOGICAL BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. NEUROLOGICAL BIOMARKERS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 22. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 23. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 24. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 25. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 26. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 29. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 30. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 32. UK NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 33. UK NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 34. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 36. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 38. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 39. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 41. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 42. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 43. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 45. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 46. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 47. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 49. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 50. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 52. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 53. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 54. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 55. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 56.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 57.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 58.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 59.F. HOFFMANN-LA ROCHE LTD.: NET SALES,
  • TABLE 60.F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 61.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 62.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 63.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 64.BIO-RAD LABORATORIES, INC.: NET SALES,
  • TABLE 65.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
  • TABLE 66.MERCK KGAA, DARMSTADT, GERMANY: COMPANY SNAPSHOT
  • TABLE 67.MERCK KGAA, DARMSTADT, GERMANY: OPERATING SEGMENTS
  • TABLE 68.MERCK KGAA, DARMSTADT, GERMANY: PRODUCT PORTFOLIO
  • TABLE 69.MERCK KGAA, DARMSTADT, GERMANY: NET SALES,
  • TABLE 70.MERCK KGAA, DARMSTADT, GERMANY: KEY STRATERGIES
  • TABLE 71.PERKINELMER INC.: COMPANY SNAPSHOT
  • TABLE 72.PERKINELMER INC.: OPERATING SEGMENTS
  • TABLE 73.PERKINELMER INC.: PRODUCT PORTFOLIO
  • TABLE 74.PERKINELMER INC.: NET SALES,
  • TABLE 75.PERKINELMER INC.: KEY STRATERGIES
  • TABLE 76.SHIMADZU CORPORATION: COMPANY SNAPSHOT
  • TABLE 77.SHIMADZU CORPORATION: OPERATING SEGMENTS
  • TABLE 78.SHIMADZU CORPORATION: PRODUCT PORTFOLIO
  • TABLE 79.SHIMADZU CORPORATION: NET SALES,
  • TABLE 80.SHIMADZU CORPORATION: KEY STRATERGIES
  • TABLE 81.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 82.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 83.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 84.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
  • TABLE 85.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
  • TABLE 86.QUANTERIX: COMPANY SNAPSHOT
  • TABLE 87.QUANTERIX: OPERATING SEGMENTS
  • TABLE 88.QUANTERIX: PRODUCT PORTFOLIO
  • TABLE 89.QUANTERIX: NET SALES,
  • TABLE 90.QUANTERIX: KEY STRATERGIES
  • TABLE 91.NEUROBIO: COMPANY SNAPSHOT
  • TABLE 92.NEUROBIO: OPERATING SEGMENTS
  • TABLE 93.NEUROBIO: PRODUCT PORTFOLIO
  • TABLE 94.NEUROBIO: NET SALES,
  • TABLE 95.NEUROBIO: KEY STRATERGIES
  • TABLE 96.BIOMERIEUX: COMPANY SNAPSHOT
  • TABLE 97.BIOMERIEUX: OPERATING SEGMENTS
  • TABLE 98.BIOMERIEUX: PRODUCT PORTFOLIO
  • TABLE 99.BIOMERIEUX: NET SALES,
  • TABLE 100.BIOMERIEUX: KEY STRATERGIES
  • TABLE 101.MYRIAD RBM (MYRIAD GENETICS, INC.): COMPANY SNAPSHOT
  • TABLE 102.MYRIAD RBM (MYRIAD GENETICS, INC.): OPERATING SEGMENTS
  • TABLE 103.MYRIAD RBM (MYRIAD GENETICS, INC.): PRODUCT PORTFOLIO
  • TABLE 104.MYRIAD RBM (MYRIAD GENETICS, INC.): NET SALES,
  • TABLE 105.MYRIAD RBM (MYRIAD GENETICS, INC.): KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION
  • FIGURE 2.NEUROLOGICAL BIOMARKERS MARKET,2021-2031
  • FIGURE 3.NEUROLOGICAL BIOMARKERS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.NEUROLOGICAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.NEUROLOGICAL BIOMARKERS MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PROTEOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF METABOLOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 17.NEUROLOGICAL BIOMARKERS MARKET,BY APPLICATION,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ALZHEIMER'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MULTIPLE SCLEROSIS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PARKINSON'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 21.NEUROLOGICAL BIOMARKERS MARKET BY REGION,2021
  • FIGURE 22.U.S. NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 23.CANADA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 24.GERMANY NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 25.FRANCE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 26.UK NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 27.REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 28.JAPAN NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 29.CHINA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 30.INDIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 31.REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 32.BRAZIL NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 33.SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 35. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 38.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 39.COMPETITIVE DASHBOARD
  • FIGURE 40.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 41.F. HOFFMANN-LA ROCHE LTD..: NET SALES ,($MILLION)
  • FIGURE 42.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)
  • FIGURE 43.MERCK KGAA, DARMSTADT, GERMANY.: NET SALES ,($MILLION)
  • FIGURE 44.PERKINELMER INC..: NET SALES ,($MILLION)
  • FIGURE 45.SHIMADZU CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 46.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
  • FIGURE 47.QUANTERIX.: NET SALES ,($MILLION)
  • FIGURE 48.NEUROBIO.: NET SALES ,($MILLION)
  • FIGURE 49.BIOMERIEUX.: NET SALES ,($MILLION)
  • FIGURE 50.MYRIAD RBM (MYRIAD GENETICS, INC.).: NET SALES ,($MILLION)
目次
Product Code: A03215

Neurological biomarkers are measurable indicators of biological state or condition of patients suffering from neurodegenerative diseases. Brain diseases require plenty of markers to reflect the metabolic impairment of different brain cells. The recent introduction of the metabolomic approach helps the study of neurological diseases based on profiling a multitude of biochemical components related to brain metabolism.

Major factors driving growth of the neurological biomarkers market include increase in geriatric population that are prone to neurological diseases, rise in head injuries, rise in prevalence of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis. For instance, according to the latest WHO data published in 2020 Parkinson's disease deaths in Australia reached 2,036 or 1.49% of total deaths. The age adjusted Death Rate is 3.35 per 100,000 of population ranks Australia #131 in the world. According to WHO update 2022, globally, disability and death due to Parkinson's disease are increasing faster than for any other neurological disorder.

For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

Moreover, neurology is one of the disciplines where personalized medicine has been emerging as an important part of treatment methods for Alzheimer's, Parkinson's and Multiple Sclerosis. Neurological biomarkers find a varied scope in personalized medicine, which eventually spurs the demand for diagnosis by incorporating neurological biomarkers. Therefore, rise in the demand for personalized medicine boost the growth of neurological biomarkers market.

Furthermore, increase in demand for minimally invasive procedures propels the adoption of neurological biomarkers product. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the growth of the neurological biomarkers market. For instance, in June 2021, Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, announced a partnership with University of California, San Francisco (UCSF) and UC Berkeley to speed up the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS) such as Alzheimer's, Parkinson's, Huntington's, Amyotrophic lateral sclerosis (ALS) and autism. UCSF and UC Berkeley had received up to $53 million from Genentech over the course of the 10-year collaboration.

However, the emerging ethical issues regarding early diagnosis of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis is expected to impede the market growth. strict government regulations and high cost for neurological biomarkers products also restrain the market growth.

Furthermore, healthcare business is predicted to witness growth, owing increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer's and Parkinson's, increase in R&D investments in drug discovery & development, and rise in awareness regarding neurological biomarker. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The neurological biomarkers market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into genomic, proteomic, metabolomic, and others. By application, the market is segregated into Alzheimer's disease, Parkinson's disease, and multiple sclerosis. 

Region wise, the market is analyzed across North America (the U.S., and Canada), Europe (Germany, France, the UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and Rest of LAMEA).

Major players profiled in the report are Biomerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGAA, Myriad Genetics, Inc., Neurobio, Perkinelmer Inc., Quanterix, Shimadzu Corporation, Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the diabetic nephropathy market to identify the prevailing opportunities
  • This study presents the competitive landscape of the global market to predict the competitive environment across various regions
  • Comprehensive analysis of factors that drive and restrict the market growth is provided
  • Region & country wise analysis is provided to understand the market trends and dynamics

Key Market Segments

By Type

  • Genomic
  • Proteomic
  • Metabolomic
  • Others

By Application

  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • Rest Of LAMEA
  • Key Market Players
    • F. HOFFMANN-LA ROCHE LTD.
    • Bio-Rad Laboratories, Inc.
    • merck kgaa, darmstadt, germany
    • PERKINELMER INC.
    • shimadzu corporation
    • Thermo Fisher Scientific, Inc.
    • Quanterix
    • Neurobio
    • bioMerieux
    • MYRIAD RBM (MYRIAD GENETICS, INC.)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: NEUROLOGICAL BIOMARKERS MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Genomic
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Proteomic
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Metabolomic
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Others
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Alzheimer's Disease
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Multiple Sclerosis
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Parkinson's Disease
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: NEUROLOGICAL BIOMARKERS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Type
    • 6.2.3 North America Market size and forecast, by Application
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Type
      • 6.2.4.1.2 Market size and forecast, by Application
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Type
      • 6.2.4.2.2 Market size and forecast, by Application
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Type
    • 6.3.3 Europe Market size and forecast, by Application
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Type
      • 6.3.4.1.2 Market size and forecast, by Application
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Type
      • 6.3.4.2.2 Market size and forecast, by Application
      • 6.3.4.3 UK
      • 6.3.4.3.1 Market size and forecast, by Type
      • 6.3.4.3.2 Market size and forecast, by Application
      • 6.3.4.4 Rest of Europe
      • 6.3.4.4.1 Market size and forecast, by Type
      • 6.3.4.4.2 Market size and forecast, by Application
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Type
    • 6.4.3 Asia-Pacific Market size and forecast, by Application
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 Japan
      • 6.4.4.1.1 Market size and forecast, by Type
      • 6.4.4.1.2 Market size and forecast, by Application
      • 6.4.4.2 China
      • 6.4.4.2.1 Market size and forecast, by Type
      • 6.4.4.2.2 Market size and forecast, by Application
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Type
      • 6.4.4.3.2 Market size and forecast, by Application
      • 6.4.4.4 Rest of Asia-Pacific
      • 6.4.4.4.1 Market size and forecast, by Type
      • 6.4.4.4.2 Market size and forecast, by Application
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Type
    • 6.5.3 LAMEA Market size and forecast, by Application
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Type
      • 6.5.4.1.2 Market size and forecast, by Application
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Type
      • 6.5.4.2.2 Market size and forecast, by Application
      • 6.5.4.3 Rest of LAMEA
      • 6.5.4.3.1 Market size and forecast, by Type
      • 6.5.4.3.2 Market size and forecast, by Application

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 F. HOFFMANN-LA ROCHE LTD.
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Bio-Rad Laboratories, Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 merck kgaa, darmstadt, germany
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 PERKINELMER INC.
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 shimadzu corporation
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Thermo Fisher Scientific, Inc.
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Quanterix
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Neurobio
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 bioMerieux
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 MYRIAD RBM (MYRIAD GENETICS, INC.)
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments